Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 77 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)  - Pipeline Review, H2 2016', provides in depth analysis on Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)  targeted pipeline therapeutics. 

The report provides comprehensive information on the Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)  targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) 
- The report reviews Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)  targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)  targeted therapeutics and enlists all their major and minor projects 
- The report assesses Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)  targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)  targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)  development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) Overview 8
Therapeutics Development 9
Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Stage of Development 9
Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Therapy Area 10
Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Indication 11
Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Pipeline Products Glance 13
Late Stage Products 13
Early Stage Products 14
Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Companies 15
Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Universities/Institutes 18
Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Therapeutics Assessment 20
Assessment by Monotherapy/Combination Products 20
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Companies Involved in Therapeutics Development 27
Aptevo Therapeutics Inc 27
ARMO Biosciences, Inc. 28
BioMAS Ltd. 29
Biotest AG 30
enGene, Inc 31
Intrexon Corporation 32
LEO Pharma A/S 33
Merck & Co., Inc. 34
P2D Bioscience 35
Pfizer Inc. 36
Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Drug Profiles 37
AM-0010 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
ANV-103 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Biologic to Activate Glutamic Acid Decarboxylase and IL-10 for Type 1 Diabetes - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Biologic to Target Insulin Receptor and IL-10 for Type 1 Diabetes - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
BT-063 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
CB-0602 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
CTLA-4 X mono-IL-10 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Dekavil - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
EG-10 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
EG-12 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Elmyelin - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Gene Therapy to Activate Interleukin 10 for Atherosclerosis - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Gene Therapy to Activate Interleukin-10 for ALS - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
LEO-32731 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
MK-1966 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
PD-2244 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Synthetic Peptides to Inhibit IL-10 and IFN Gamma for Cancer, Viral Infections and Inflammatory Diseases - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
XT-101 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
XT-150 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Dormant Projects 61
Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Discontinued Products 64
Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Featured News & Press Releases 65
Sep 26, 2016: ARMO BioSciences Announces Data Presentations at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 65
Aug 15, 2016: ARMO BioSciences Announces Publication of AM0010 Clinical Data in Advanced Solid Tumor Patients in Journal of Clinical Oncology 66
Jun 06, 2016: ARMO BioSciences AM0010 Demonstrates Promising Clinical Data as an Immuno-oncology Monotherapy and in Combination with an Anti-PD-1 Checkpoint Inhibitor in Advanced Solid Tumors, Including Immune-Resistant Cancers 67
Apr 20, 2016: ARMO BioSciences Announces AM0010 Clinical Data to be Presented at the American Society of Clinical Oncology Annual Meeting in June 2016 68
Mar 31, 2016: Xalud Therapeutics Discovers Potential Solution for Opioid Abuse Crisis 69
Mar 16, 2016: ARMO BioSciences to Present New Clinical Trial Results for AM0010 at Upcoming Medical Conferences 70
Jan 08, 2016: ARMO BioSciences to Present at the 34th Annual J.P. Morgan HealthCare Conference 70
Oct 30, 2015: ARMO BioSciences Presents Positive Phase 1 Trial Results of AM0010 at Upcoming Medical Conferences 71
Oct 06, 2015: Biotest reaches the next milestone in the clinical development of its monoclonal antibody BT-063 by starting the clinical phase IIa trial in the indication systemic lupus erythematosus 71
Jun 01, 2015: ARMO BioSciences Announces Efficacy and Safety Data for Immuno-Oncology Program with Novel Mechanism of Action 72
May 13, 2015: ARMO BioSciences Announces Presentation on Promising Immuno-Oncology Program at 2015 ASCO Annual Meeting 73
Jun 23, 2014: Cytovance Biologics selected for GMP manufacture of AM0010 for ARMO BioSciences 73
Nov 25, 2013: ARMO BioSciences Initiates Phase 1 Clinical Trial of First-In-Class Cancer Immunotherapy 73
Apr 11, 2012: University Of Leuven And ActoGeniX Announce Study Results Of ActoBiotic In Treatment Of Type 1 Diabetes 74
Sep 30, 2009: Biotest AG Announces Initiation of Clinical development of BT-063 75
Appendix 76
Methodology 76
Coverage 76
Secondary Research 76
Primary Research 76
Expert Panel Validation 76
Contact Us 76
Disclaimer 77

List of Tables

Number of Products under Development for, H2 2016 9
Number of Products under Development by Therapy Area, H2 2016 10
Number of Products under Development by Indication, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Early Stage Products, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Development by Companies, H2 2016 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H2 2016 18
Products under Investigation by Universities/Institutes, H2 2016 19
Assessment by Monotherapy/Combination Products, H2 2016 20
Number of Products by Stage and Mechanism of Action, H2 2016 22
Number of Products by Stage and Route of Administration, H2 2016 24
Number of Products by Stage and Molecule Type, H2 2016 26
Pipeline by Aptevo Therapeutics Inc, H2 2016 27
Pipeline by ARMO Biosciences, Inc., H2 2016 28
Pipeline by BioMAS Ltd., H2 2016 29
Pipeline by Biotest AG, H2 2016 30
Pipeline by enGene, Inc, H2 2016 31
Pipeline by Intrexon Corporation, H2 2016 32
Pipeline by LEO Pharma A/S, H2 2016 33
Pipeline by Merck & Co., Inc., H2 2016 34
Pipeline by P2D Bioscience, H2 2016 35
Pipeline by Pfizer Inc., H2 2016 36
Dormant Projects, H2 2016 61
Dormant Projects (Contd..1), H2 2016 62
Dormant Projects (Contd..2), H2 2016 63
Discontinued Products, H2 2016 64